The prognostic value of occult peritoneal tumor cells, detected by ddPCR for KRAS, in patients with (borderline) resectable pancreatic cancer
Not yet recruiting
- Conditions
- metastasespancreatic cancer10027656
- Registration Number
- NL-OMON51142
- Lead Sponsor
- OLVG
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- Not specified
- Target Recruitment
- 36
Inclusion Criteria
- Indication for laparascopic cholecystectomy
- Age > 18
Exclusion Criteria
A medical history of cancer
Study & Design
- Study Type
- Observational invasive
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method <p>Presence or absence of KRAS mutation in peritoneal fluid.</p><br>
- Secondary Outcome Measures
Name Time Method <p>-</p><br>
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
How does KRAS mutation detection via ddPCR in NL-OMON51142 correlate with peritoneal metastasis in borderline resectable pancreatic cancer?
What is the comparative effectiveness of ddPCR-based KRAS analysis versus traditional imaging for prognosis in resectable pancreatic cancer?
Which biomarkers, including KRAS mutations, are most predictive of survival in patients with borderline resectable pancreatic cancer?
What are the potential risks and management strategies for invasive peritoneal fluid sampling in pancreatic cancer trials?
How does KRAS mutation status detected by ddPCR influence neoadjuvant therapy choices in borderline resectable pancreatic cancer?